SUBSCRIBE
IQVIA Blog Digest
For all the latest industry insights, please subscribe to the IQVIA U.S. blog digest.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Harness DataPharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Evaluate Risk
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Enhance Your SpecialtyU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSBlog
Is Your Real World Data Credible? Part 1 in a series
The use of established frameworks to evaluate credibility
Mar 08, 2021
Part one of this two part blog series will help answer and demonstrate the need for credible real world data and how utilizing established frameworks can help to evaluate fit-for-purpose.
Real World Data: A powerful tool for informed decision making
Real world data (RWD) are data collected outside of clinical trials as part of routine clinical practice, such as data found in electronic medical records (EMRs), registries, insurance claims, and mobile devices. Real world evidence (RWE) is derived from RWD and can support informed decisions by patients, providers, regulators, and payers throughout the drug's lifecycle around the use, benefits, and risk of medical products and devices.
The adoption of RWD for regulatory and market access purposes has accelerated through the confluence of the following key healthcare trends.
First, RWD is becoming increasingly available for use, driven in part by the advent of new analytic techniques and the widespread, positive effects of the 21st Century Cures Act. New data access channels and RWD types are emerging, fueled by the adoption of healthcare interoperability standards and the growth of digital health and telemedicine, trends that have accelerated in response to the COVID-19 pandemic.
Second, clinical trial designs that incorporate RWE (e.g. external comparators and pragmatic trials) have gained increasing acceptance with regulators for initial approvals and label extensions.
Third, RWE is facilitating the shift from volume to value-based healthcare. Shifting reimbursement schemes and outcomes-based contracting strategies rely on RWD to inform the actual use, outcomes, and value of products in the real world.
Data credibility frameworks – an introduction
Although data are becoming easier to access than in the past, all data sources are not equally suited or credible to answer specific research questions. The term “fit-for-purpose” is often used to describe a data source that can answer certain questions with accuracy and credibility. Assessing the fit of RWD sources is context dependent. A given dataset may be well suited to address a specific set of research questions, and poorly suited to answer another set. To determine if a data source is “fit-for-purpose,” existing data credibility frameworks that have emerged in the last few years can be leveraged.
The Grace Checklist pioneered the idea that RWD could be evaluated on the merits of how well data addresses a particular research question. In 2018, the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) published guidance for assessing RWD, emphasizing consistency, completeness, accuracy, and timeliness. The Duke Margolis Center for Health policy also published guidance that focused on the completeness, transparency, generalizability, timeliness, and scalability of RWD. The theme running through each is to establish data quality standards for creating RWE that is credible and useful for internal and external stakeholders, as well as for regulators.
Leveraging credibility frameworks to assess RWD
Evaluation of data sources is context dependent, but once a list of potential RWD sources has been assembled, a qualitative and quantitative analysis should be conducted on each of the relevant RWD sources identified through secondary research.
Engaging with the data owners to understand capabilities, collection methods, data quality controls, data provenance, lineage, and missing data can identify strengths and weaknesses of the data. In general, each of the data credibility frameworks advises that when assessing data and its fitness for purpose, important consideration must be given to:
- Missing data/errors and correction methods
- Defining the lifecycle, validity, and integrity of data
- Granularity of clinical data collected to ensure sufficient context
- Publication and use history
After refining the list based on a qualitative examination, a quantitative analysis will help determine if the data meet the pre-specified inclusion/exclusion criteria, target sample size needs, and sufficient data quality and completeness.
Once assessed using a standardized approach, each data source can be evaluated to weigh the data suitability and credibility for its intended audience. FIGURE 1 shows a sample data credibility assessment matrix. It is important to note that data set weakness in one or more dimensions does not necessarily mean that the source must be excluded. Some data sets may warrant additional data extraction methods, such as natural language processing (NLP), tokenization, and linking to other data sources, or enrichment of secondary data through prospective primary data collection.
Figure 1: Qualitative and quantitative assessments of RWD sources highlight areas of strength as well as potential gaps.
Identifying credible data source is only one step. Ensuring the RWD source or set of sources must be fit-for-purpose to address stakeholder needs is also essential. Part two in this blog series will discuss how to identify the right set of data sources to address stakeholders’ broad evidence needs.
On-Demand Webinar: Is Your Real World Data Credible?
Tips to identify and evaluate the right RWD for your organization.